Go offline with the Player FM app!
Gene testing for all breast cancer patients with second primary malignancy, atezolizumab for TNBC, pralsetinib for NSCLC, and more
Manage episode 272090500 series 2608031
Hematology/Oncology News:
Study supports multigene panel testing for all breast cancer patients with second primary cancers: https://bit.ly/3m6RyOGSource: https://bit.ly/2ZKXund
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results: https://bit.ly/35rqzrl Alert: https://bit.ly/2Reh1HMTrial: https://bit.ly/2ZqqIqX
Pralsetinib: Second drug for RET+ NSCLC approved in U.S.: https://bit.ly/3bTdGaz
Unexpected results in new COVID-19 ‘cytokine storm’ data: https://bit.ly/3k8fIGL JAMA research letter: https://bit.ly/35ubxB4
You can email the show at podcasts@mdedge.com
100 episodes
Manage episode 272090500 series 2608031
Hematology/Oncology News:
Study supports multigene panel testing for all breast cancer patients with second primary cancers: https://bit.ly/3m6RyOGSource: https://bit.ly/2ZKXund
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results: https://bit.ly/35rqzrl Alert: https://bit.ly/2Reh1HMTrial: https://bit.ly/2ZqqIqX
Pralsetinib: Second drug for RET+ NSCLC approved in U.S.: https://bit.ly/3bTdGaz
Unexpected results in new COVID-19 ‘cytokine storm’ data: https://bit.ly/3k8fIGL JAMA research letter: https://bit.ly/35ubxB4
You can email the show at podcasts@mdedge.com
100 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.